Nifty Pharma News
Nifty 50, Sensex fall for 4th day, shed 0.5% as bears continue to rule; auto, pharma stocks top drags
The Indian stock market faced selling pressure on February 21, with auto and pharma stocks dragging indices down for the fourth session. Nifty 50 fell 0.51% to 22,795, while Sensex dropped 0.52%. Global trade tensions prompt investors to seek safe havens like gold.
3 min read21 Feb 2025Nifty Pharma drops over 2%, 19 index stocks tumble up to 7%. What triggered this fall?
Indian pharma stocks experienced heavy selling on February 10, influenced by weak earnings and concerns over possible U.S. tariffs. The Nifty Pharma index fell 2.10% with major firms like Alkem and Ipca suffering significant losses.
1 min read10 Feb 2025Nifty Pharma index down over 7% in last three days; why are pharma stocks falling?
The Nifty Pharma index fell nearly 3% in intraday trade on January 28, marking its third consecutive session of decline, with Granules India, Biocon, Sun Pharma, and Lupin being the biggest losers.
2 min read28 Jan 2025Will Donald Trump turn out to be a bitter pill for Indian pharma stocks again?
The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug production. It said that expanding US drug manufacturing on a large scale is a counter-intuitive move, as it would likely lead to higher drug prices.
4 min read23 Jan 2025Biocon stock zooms over 8% on Psoriasis drug approval from Japan, Jefferies rating upgrade
Biocon shares rose 8.5% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab. Jefferies upgraded its rating to ’Hold’ with a target of ₹400, citing favorable FDA status for its Bengaluru facility.
2 min read7 Jan 20252025: The pharma stock poised to outperform
As 2024 ends with market turbulence, the pharmaceutical sector is emerging as a beacon of stability and growth, with this stock leading the pack.
3 min read24 Dec 2024Piramal Pharma share price jumps 4.5% after JM Financial issues ’buy’ rating, sees 36% upside
JM Financial has initiated coverage on Piramal Pharma with a ’Buy’ rating and a target price of ₹340, reflecting a 36% upside potential. The firm anticipates over 17% CAGR growth in Piramal’s CDMO business, driven by strong demand and competitive advantages in the expanding CRDMO industry.
2 min read17 Dec 2024Mankind Pharma shares zoom 7% to new record high after Investec initiates coverage with ’buy’ rating, sees 36% upside
Shares of Mankind Pharma rose 7% after Investec initiated coverage with a ’buy’ rating. The company, known for its 36 brands, is well-positioned in the growing Indian pharmaceutical market, driven by increased healthcare expenditure and an ageing population.
2 min read20 Sep 2024Zydus Lifesciences stock slides 16% from recent peak, Elara Capital sees a buy opportunity; raises target price
Elara Capital sees Zydus Lifesciences’ stock correction as a buying opportunity, upgrading it to ’buy’ with a target of ₹1,497. Despite expected revenue declines in FY27, the company’s focus on specialty drugs and new products should offset these challenges, maintaining growth momentum.
3 min read3 Sep 2024Pharma stocks see 3rd straight month of gains in August, Mankind Pharma and 6 others rise up to 23%
Pharma stocks continued their bullish trend in August, with the Nifty Pharma index rising by 6.61%, driven by strong performances from Mankind Pharma and others. The index has gained 36% this year, benefiting from increased US sales, new product launches, and strong quarterly earnings.
3 min read2 Sep 2024Popular Topics
Budget
The Union Budget contains details about the estimated receipts and the expenditure of the government for a particular fiscal year. The Budget is allotted for the upcoming fiscal year, which runs from 1st April to 31st March of the next year. Here is a quick guide on how the Union Budget is prepared